1078 related articles for article (PubMed ID: 18606915)
1. The impact of prevention on reducing the burden of cardiovascular disease.
Kahn R; Robertson RM; Smith R; Eddy D
Circulation; 2008 Jul; 118(5):576-85. PubMed ID: 18606915
[TBL] [Abstract][Full Text] [Related]
2. The impact of prevention on reducing the burden of cardiovascular disease.
Kahn R; Robertson RM; Smith R; Eddy D
Diabetes Care; 2008 Aug; 31(8):1686-96. PubMed ID: 18663233
[TBL] [Abstract][Full Text] [Related]
3. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
4. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
Whitfield MD; Gillett M; Holmes M; Ogden E
Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
[TBL] [Abstract][Full Text] [Related]
5. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
6. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
Huse DM; Song X; Ozminkowski RJ; Maguire J; Williams SA; Borok GM; McDonough K
Clin Ther; 2006 Sep; 28(9):1425-42. PubMed ID: 17062315
[TBL] [Abstract][Full Text] [Related]
7. Effect of smoking cessation advice on cardiovascular disease.
Eddy DM; Peskin B; Shcheprov A; Pawlson G; Shih S; Schaaf D
Am J Med Qual; 2009; 24(3):241-9. PubMed ID: 19332865
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004.
Ghandehari H; Kamal-Bahl S; Wong ND
Am Heart J; 2008 Jul; 156(1):112-9. PubMed ID: 18585505
[TBL] [Abstract][Full Text] [Related]
9. Socioeconomic status and trends in disparities in 4 major risk factors for cardiovascular disease among US adults, 1971-2002.
Kanjilal S; Gregg EW; Cheng YJ; Zhang P; Nelson DE; Mensah G; Beckles GL
Arch Intern Med; 2006 Nov; 166(21):2348-55. PubMed ID: 17130388
[TBL] [Abstract][Full Text] [Related]
10. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
Sorensen SV; Frick KD; Wade A; Simko R; Burge R
Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
[TBL] [Abstract][Full Text] [Related]
11. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System.
Ajani UA; Ford ES; Greenland KJ; Giles WH; Mokdad AH
Am J Prev Med; 2006 Jan; 30(1):74-7. PubMed ID: 16414427
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
Greving JP; Buskens E; Koffijberg H; Algra A
Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
[TBL] [Abstract][Full Text] [Related]
14. Aspirin use in the prevention of cardiovascular events.
Crutcher JM; Mallonee S; Daniels C
J Okla State Med Assoc; 2007 Oct; 100(10):383-7. PubMed ID: 18085095
[TBL] [Abstract][Full Text] [Related]
15. Secondary prevention for acute coronary syndrome in rural South Australia: are drugs best? What about the rest?
Wachtel TM; Kucia AM; Greenhill JA
Rural Remote Health; 2008; 8(4):967. PubMed ID: 18855517
[TBL] [Abstract][Full Text] [Related]
16. Medical care costs among patients with established cardiovascular disease.
Nichols GA; Bell TJ; Pedula KL; O'Keeffe-Rosetti M
Am J Manag Care; 2010 Mar; 16(3):e86-e93. PubMed ID: 20205493
[TBL] [Abstract][Full Text] [Related]
17. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.
Annemans L; Lamotte M; Kubin M; Evers T; Verheugt FW
Int J Clin Pract; 2006 Sep; 60(9):1129-37. PubMed ID: 16939558
[TBL] [Abstract][Full Text] [Related]
18. Estimating the impact of adding C-reactive protein as a criterion for lipid lowering treatment in the United States.
Woloshin S; Schwartz LM; Kerin K; Welch HG
J Gen Intern Med; 2007 Feb; 22(2):197-204. PubMed ID: 17356986
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of community-based physical activity interventions.
Roux L; Pratt M; Tengs TO; Yore MM; Yanagawa TL; Van Den Bos J; Rutt C; Brownson RC; Powell KE; Heath G; Kohl HW; Teutsch S; Cawley J; Lee IM; West L; Buchner DM
Am J Prev Med; 2008 Dec; 35(6):578-88. PubMed ID: 19000846
[TBL] [Abstract][Full Text] [Related]
20. Modelling the potential impact of population-wide and targeted high-risk blood pressure-lowering strategies on cardiovascular disease in China.
Qin X; Jackson R; Marshall R; Lee L; Cao W; Zhan S; Hu Y
Eur J Cardiovasc Prev Rehabil; 2009 Feb; 16(1):96-101. PubMed ID: 19237999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
